DCK and glioblastoma: We have previously demonstrated GJIC-dependent bystander effects with suicide gene therapy based on the delivery of a catalytically-enhanced variant of the deoxycytidine kinase (dCK) suicide gene in a U87 model of glioblastoma-astrocytoma [21].